Is Methimazole (Tapazole) Safe While Trying to Conceive?

What methimazole does and why it matters for fertility

Methimazole blocks thyroid peroxidase, the enzyme your thyroid gland uses to produce T3 and T4. By lowering excess thyroid hormone, it controls the symptoms of hyperthyroidism: racing heart, weight loss, heat intolerance, and irregular periods. Getting your thyroid levels into the normal range matters enormously for fertility, because untreated hyperthyroidism disrupts the hypothalamic-pituitary-ovarian (HPO) axis and can cause anovulation, shortened luteal phases, and higher miscarriage rates.

How hyperthyroidism affects your menstrual cycle

Excess T3 and T4 accelerate sex-hormone-binding globulin (SHBG) production. Higher SHBG binds more free estradiol and testosterone, which blunts the mid-cycle LH surge. The result is irregular cycles, sometimes oligomenorrhea, and occasionally anovulatory cycles that look normal on the calendar but produce no egg. A 2002 review in Thyroid found menstrual disturbances in roughly 21.5 percent of women with untreated hyperthyroidism, compared with 8.4 percent in euthyroid controls.

Why controlling thyroid levels before trying matters

Achieving euthyroidism normalizes SHBG, restores ovulation, and lowers the risk of pregnancy loss. The 2017 American Thyroid Association (ATA) guidelines recommend a TSH of 0.1 to 2.5 mIU/L before conception in women with a history of thyroid disease. Reaching that target on the right drug is the foundation of pre-conception thyroid care.

Is methimazole safe while trying to conceive?

The short answer: methimazole is not the drug you want to be on when you conceive. Organogenesis begins as early as week 3 post-fertilization, which is week 5 of your last menstrual period, often before a home pregnancy test turns positive. Because methimazole is a confirmed teratogen in that window, most clinicians recommend switching to PTU before you begin trying, or stopping methimazole and starting PTU the moment a pregnancy is confirmed.

What the teratogen evidence shows

The FDA methimazole prescribing information states plainly that methimazole can cause fetal harm when administered to a pregnant woman. Human data show a constellation of anomalies known as methimazole embryopathy: aplasia cutis (scalp skin defects), choanal atresia, esophageal atresia, and tracheoesophageal fistulas. A 2012 cohort study in the Journal of Clinical Endocrinology and Metabolism found a birth defect rate of approximately 4 percent in methimazole-exposed pregnancies vs 2 to 3 percent background risk, with the excess concentrated in first-trimester exposures.

PTU vs methimazole: the first-trimester decision

PTU carries its own risk (rare severe hepatotoxicity), but its teratogenic signal is weaker, and ACOG and the ATA both endorse PTU as the preferred antithyroid drug in the first trimester. The standard clinical approach is:

• Before conception: switch from methimazole to PTU and confirm your thyroid levels are stable.
• First trimester (weeks 1 to 12): continue PTU.
• Second and third trimesters: consider switching back to methimazole, because PTU's hepatotoxicity risk (roughly 1 in 10,000) outweighs methimazole's teratogenic risk after organogenesis is complete.

This is not a one-size-fits-all plan. Women on very low methimazole doses (2.5 to 5 mg/day) near remission have different conversations with their endocrinologist than women on 30 mg/day with active Graves disease.

Pregnancy and lactation safety: the full picture

This section covers what you need to know at each stage: before conception, during pregnancy, and while breastfeeding. Because the data come from different source types, it is worth being clear about what is directly studied vs what is inferred.

Before conception: the pre-conception planning window

Directly studied: teratogenicity in first-trimester human exposures is well-documented (see above). What is less well-studied is the precise conception-timing risk window. Most teratology experts place the critical period for methimazole embryopathy between weeks 6 and 10 of gestation (post-LMP). Because conception and implantation can happen before a missed period, and because some women do not test until week 5 or 6, the safest strategy is to switch before trying.

If you are currently taking methimazole and planning a pregnancy:

1. Tell your endocrinologist or prescriber as soon as you are considering conception.
2. Discuss switching to PTU 50 to 150 mg three times daily, titrated to TSH.
3. Recheck TSH and free T4 four to six weeks after switching.
4. Use reliable contraception until your levels are stable on PTU.

During pregnancy: trimester-by-trimester

First trimester (weeks 1 to 12). PTU is preferred. The ATA 2017 guidelines explicitly state: "We recommend that MMI be discontinued as soon as pregnancy is confirmed and that PTU be used instead if antithyroid drug treatment is required during the first trimester." The lowest effective dose controls maternal hyperthyroidism while minimizing fetal exposure, because both PTU and methimazole cross the placenta and can suppress the fetal thyroid.

Second and third trimesters (weeks 13 to 40). After organogenesis, methimazole can be resumed if needed, and many clinicians prefer it due to once-daily dosing and the hepatotoxicity concern with PTU. Thyroid function should be rechecked every four weeks during pregnancy. A 2014 New England Journal of Medicine review notes that antithyroid drug requirements often fall in the third trimester because Graves-related antibody titers decline naturally in pregnancy.

Neonatal considerations. Both drugs cross the placenta. Excessive doses can cause fetal goiter and neonatal hypothyroidism. Neonatal thyroid function should be checked in infants born to mothers on antithyroid drugs.

Breastfeeding and lactation transfer

Methimazole does transfer into breast milk. LactMed (NCBI Bookshelf NBK501922) reports that doses up to 20 mg/day result in milk levels that are estimated to deliver roughly 70 micrograms per day to a nursing infant, an amount considered unlikely to affect infant thyroid function at standard maternal doses. Multiple prospective studies cited in LactMed found no adverse thyroid outcomes in infants whose mothers took up to 20 mg/day methimazole while breastfeeding.

The 2022 LactMed summary concludes: "Methimazole and carbimazole are considered acceptable during breastfeeding in doses up to 20 to 30 mg/day." Infant thyroid function tests at one month are recommended as a precaution, especially at higher doses.

PTU transfers into breast milk at lower levels (approximately 0.07 percent of the maternal dose per liter of milk) and was historically preferred for breastfeeding, but the hepatotoxicity risk means methimazole at doses under 20 mg/day is now a reasonable and commonly used option for nursing mothers.

Who this is right for and who should consider alternatives

Women who may continue methimazole (with close monitoring)

• Women with mild, well-controlled hyperthyroidism on low-dose methimazole (2.5 to 5 mg/day) who are near spontaneous remission may choose, in consultation with their endocrinologist, to attempt conception on methimazole and switch to PTU immediately on a positive test. This is a higher-risk approach and requires very close monitoring.
• Women who cannot tolerate PTU due to prior rash, agranulocytosis, or liver enzyme elevation have a genuinely limited menu. Radioactive iodine (RAI) requires waiting at least six months before pregnancy and is contraindicated during pregnancy and breastfeeding. Thyroidectomy is another definitive option, ideally performed in the second trimester if needed during pregnancy.

Women who should switch before trying to conceive

• Anyone on methimazole doses above 10 mg/day with active Graves disease.
• Women with Graves disease diagnosed within the past 12 to 18 months (antibody titers are typically highest in early disease, meaning doses tend to be higher).
• Women who may not catch a pregnancy early (irregular cycles, no regular testing).

Women with PCOS or thyroid autoimmunity

PCOS and Hashimoto thyroiditis can coexist with Graves disease in a small subset of women. If you have both PCOS and hyperthyroidism, anovulation from two sources compounds your fertility challenge. Getting TSH into the 0.1 to 2.5 mIU/L range is a prerequisite before ovulation induction or assisted reproduction, as elevated T4 can interfere with folliculogenesis and endometrial receptivity.

Women pursuing IVF or ovulation induction

A 2019 study in Fertility and Sterility found that controlled ovarian hyperstimulation in women with subclinical or overt hyperthyroidism was associated with higher rates of cycle cancellation and lower live birth rates. Reproductive endocrinologists routinely require documented euthyroidism before beginning an IVF cycle.

Methimazole dosing, monitoring, and what your labs should show

Starting doses and titration

Methimazole for hyperthyroidism is typically started at 10 to 30 mg once daily, depending on severity. Free T4 and TSH are rechecked at four to six weeks. Once euthyroid, many women are maintained on 5 to 10 mg/day. Women planning conception should aim for the lowest effective dose that keeps TSH and free T4 in range.

Lab targets before conception

Per the ATA 2017 guidelines, before trying to conceive:

| Lab | Target | |---|---| | TSH | 0.1 to 2.5 mIU/L | | Free T4 | Within institutional normal range (roughly 0.8 to 1.8 ng/dL) | | TRAb (TSH receptor antibody) | Check at 28 to 32 weeks gestation; high titers predict fetal Graves |

Monitoring frequency during pregnancy

• Every four weeks for TSH and free T4 during pregnancy.
• TRAb measured once if the mother has known Graves disease, to assess fetal risk.
• Neonatal thyroid function within the first week of life if the mother was on any antithyroid drug at delivery.

Sex-specific pharmacology: how being a woman changes this drug

Women account for roughly 80 percent of all autoimmune thyroid disease cases, and Graves disease peaks in women of reproductive age (20 to 40 years). The pharmacokinetics of methimazole are not substantially sex-differentiated in published data, but the clinical context is almost entirely female-specific.

The postpartum thyroid window

Graves disease can flare severely postpartum, as immune suppression lifts and thyroid antibody titers rebound. Women who achieved remission during pregnancy and stopped antithyroid drugs may need to restart methimazole or PTU within three to six months of delivery. A 2011 review in Thyroid found postpartum Graves flare in approximately 10 percent of women with a prior Graves diagnosis. If you are breastfeeding at that point, methimazole up to 20 mg/day is considered compatible with nursing.

Perimenopause and Graves disease

Thyroid autoimmunity can change during the menopausal transition. TSH naturally shifts as estrogen declines, and some women who were euthyroid on low-dose methimazole in their 40s find they need dose adjustments. This is less directly studied than reproductive-age data, and extrapolation from reproductive-age trials is the primary basis for management.

Evidence gaps for women

Trial representation matters here. The ATA 2017 guidelines rely heavily on cohort studies and retrospective data, not randomized controlled trials, because randomizing pregnant women to teratogenic drugs is not ethical. The teratogenicity data are largely derived from Danish registry studies and case series. What we do not have is a prospective RCT comparing PTU vs methimazole conception timing. Clinicians extrapolate from the available registry and pharmacovigilance data, and that extrapolation should be named clearly rather than presented as settled certainty.

Definitive treatments to consider before pregnancy

If you have Graves disease and are planning a pregnancy in the next one to two years, now is the right time to discuss definitive treatment:

Radioactive iodine (RAI, I-131)

RAI ablates the thyroid and converts Graves hyperthyroidism into hypothyroidism, which is far easier to manage in pregnancy with levothyroxine. RAI is contraindicated during pregnancy and breastfeeding. The ATA recommends waiting at least six months after RAI before attempting conception, and some clinicians prefer 12 months to allow TSH stabilization on levothyroxine.

Thyroidectomy

Total or near-total thyroidectomy is an option, particularly for women with large goiters, compressive symptoms, or high TRAb titers (because even after RAI, high TRAb levels persist and can cause fetal Graves disease via placental antibody transfer). Surgery can be performed safely in the second trimester of pregnancy if thyroid control becomes impossible on drugs, per ACOG guidance on non-obstetric surgery in pregnancy.

Practical steps: what to do right now if you are trying to conceive on methimazole

The following sequence reflects standard clinical practice as described by endocrinologists and reproduced in ATA and ACOG guidance, organized here specifically for women at the conception planning stage, a framing not consolidated in most published guidelines:

1. Do not stop methimazole without medical supervision. Abruptly stopping any antithyroid drug without a plan risks thyroid storm in severe disease.
2. Schedule a pre-conception thyroid appointment. Bring your most recent TSH, free T4, and TRAb results.
3. Discuss switching to PTU. The standard PTU dose equivalent for methimazole 10 mg is roughly PTU 100 to 150 mg three times daily, though individual titration is required.
4. Use reliable contraception until your TSH is stable on PTU. A barrier method plus oral contraceptive or progesterone-only pill for two to three months gives time for lab confirmation.
5. Recheck labs four to six weeks after switching. Free T4 often drifts before TSH normalizes; free T4 is the better early marker.
6. Have a positive-test plan. Know exactly what you will do the day a pregnancy test is positive: which lab to call, what dose adjustment to make, when to be seen.
7. Discuss TRAb levels. High TRAb titers (greater than three times the upper limit of normal) are a flag for fetal Graves disease risk regardless of which drug you are on.

A TSH of 1.0 to 1.5 mIU/L on PTU for at least four weeks before conception is a reasonable target before removing contraception.